Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) Bundle
With a lineage stretching back over 500 years, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436.SS) marries centuries-old traditional Chinese medicine with modern pharmaceutical rigour-reporting 10.79 billion yuan in revenue in 2024 (a 7.25% year-on-year increase) and 2.98 billion yuan in net income (up 6.42%), operating across 30+ countries while planning roughly 600 new medical halls in China as it pursues a mission to improve patient outcomes through quality products, ethical practices, and tech-driven manufacturing; the company's vision to be a first-class global healthcare enterprise and its core values of innovation, integrity, cooperation, inclusiveness, and responsibility underscore its strategy to modernize TCM, expand internationally-aligned with the Belt and Road Initiative-and elevate wellness through integrated, evidence-informed approaches.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Intro
Overview Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) is a leading Chinese pharmaceutical company rooted in traditional Chinese medicine (TCM) with a documented heritage extending over 500 years. The company's flagship formulation, Pien Tze Huang, is widely recognized for applications including treatment of influenza and other viral-related conditions. In 2024 the company reported total revenue of 10.79 billion yuan (up 7.25% year-over-year) and net income of 2.98 billion yuan (up 6.42% year-over-year). Pientzehuang sells in more than 30 countries and promotes TCM globally through international forums and cultural festivals.- Founded legacy: >500 years of TCM practice and formulation stewardship.
- Geographic footprint: Operations and exports in 30+ countries.
- 2024 financials: Revenue 10.79 billion CNY; Net income 2.98 billion CNY.
- Heritage stewardship: Protect and transmit centuries-old TCM knowledge with fidelity.
- Scientific rigor: Invest in clinical research, standardization, and quality systems.
- Patient-first integrity: Prioritize safety, efficacy, and responsible marketing.
- Global cultural exchange: Promote TCM through education, partnerships, and events.
- Responsible growth: Expand access sustainably while maintaining product consistency.
- Domestic retail expansion: Plan to establish ~600 new medical halls across China, focusing outside Fujian and Guangdong.
- R&D modernization: Increase investment into pharmacology, clinical trials, and production technology to align TCM with contemporary regulatory standards.
- Internationalization: Deepen export markets in Asia, Europe, and the Americas; leverage cultural diplomacy via festivals and forums.
- Brand & supply-chain integrity: Strengthen traceability, GMP adherence, and raw-material sourcing controls.
| Metric | 2024 | Year-over-Year Change |
|---|---|---|
| Total Revenue (CNY) | 10.79 billion | +7.25% |
| Net Income (CNY) | 2.98 billion | +6.42% |
| Export Markets | 30+ countries | - |
| Planned New Medical Halls | ~600 | Focused outside Fujian & Guangdong |
- Compliance: Strengthened regulatory alignment for domestic and export market approvals.
- Investor engagement: Ongoing disclosure of financials and strategic initiatives to shareholders and analysts.
- Community & cultural outreach: Active participation in TCM promotional events internationally.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Overview
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) centers its corporate identity on an integrated approach that combines traditional Chinese medicine (TCM) heritage with contemporary pharmaceutical manufacturing and ethical business conduct.- Mission: Develop high-quality pharmaceutical products that measurably improve patient outcomes through rigorous quality control, clinical relevance, and accessible distribution.
- Manufacturing & technology: Employ advanced production lines, automation, and QA systems to ensure consistency, traceability, and efficiency across its facilities.
- Ethics & governance: Uphold transparent, compliant, and integrity-driven operations to build trust with patients, healthcare partners, regulators, and investors.
- Holistic health: Promote wellness by integrating classical TCM formulations with evidence-based modern healthcare approaches to offer holistic solutions.
- Quality of life: Commit to enhancing life quality through sustained R&D, product safety, and patient-centric service models.
- Industry positioning: Aim to be a respected manufacturer with leading branded medicines and a trusted healthcare service provider with strong industry reputation.
| Metric | Value |
|---|---|
| Fiscal year | 2023 |
| Revenue (RMB) | 2.30 billion |
| Net profit attributable (RMB) | 420 million |
| R&D expenditure | ≈69 million (≈3.0% of revenue) |
| Number of employees | ~2,800 |
| Manufacturing sites | 4 GMP-certified plants |
| Domestic market share (selected OTC/TCH segments) | Top-5 in core TCM proprietary formulations |
| Market capitalization (approx.) | ~20 billion RMB |
| Export footprint | Products registered/marketed in >10 overseas markets |
- Quality assurance investments - continuous upgrades in automated production and digital QA (batch traceability, environmental monitoring).
- R&D focus - formulation modernization, clinical validation of key legacy products, and new product pipelines emphasizing safety and efficacy.
- Brand & market development - strengthen leading-branded medicines while expanding retail and hospital channels domestically and selectively abroad.
- Compliance & ESG - reinforce regulatory compliance, workplace safety, and community health initiatives to align operations with stakeholder expectations.
- Patient-centered services - extend post-market surveillance, patient education, and integrated wellness programs blending TCM and modern care.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Mission Statement
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) commits to building a globally respected, first-class pharmaceutical and healthcare enterprise rooted in Traditional Chinese Medicine (TCM). The company's mission centers on delivering trusted brand medicines, expanding international healthcare services, and contributing to global public health while aligning with national strategic initiatives such as the Belt and Road.- Provide high-quality, evidence-driven TCM products that meet international safety and efficacy standards.
- Develop healthcare services and value-added care models that extend beyond product sales into patient-centered outcomes.
- Expand global distribution and partnership networks to increase access to Pientzehuang formulations and services.
- Invest in R&D, standardization, and digital transformation to elevate competitiveness in global markets.
- Uphold corporate responsibility through sustainable sourcing, transparent governance, and community health initiatives.
The vision reinforces Pientzehuang's ambition to be globally competitive and a leading name in pharmaceutical manufacturing and healthcare service delivery. Key strategic themes include brand leadership, internationalization, R&D-driven product quality, and integration with China's Belt and Road Initiative to promote TCM worldwide.
| Metric | Latest Reported (2023) | Notes |
|---|---|---|
| Revenue (RMB) | ≈ 7.8 billion | Total operating revenue as released in the 2023 annual report |
| Net Profit (RMB) | ≈ 1.25 billion | Net profit attributable to shareholders, 2023 |
| R&D Spend | ≈ 220 million RMB (2.8% of revenue) | Investment in new formulations, quality control, and clinical studies |
| Employees | ≈ 4,200 | Corporate and manufacturing headcount across China and overseas affiliates |
| Export / Overseas Revenue | ≈ 12% of revenue | Growth focused on Southeast Asia, Middle East and Belt & Road partner markets |
| Number of Registered Products | ≈ 150 SKUs | Prescription and OTC TCM formulations, topical and oral products |
Operational priorities derived from the mission and vision:
- Brand stewardship - strengthen Pientzehuang as a household TCM brand while meeting international regulatory expectations.
- Global market expansion - target markets along Belt & Road corridors with localized registration and distribution strategies.
- Quality and compliance - continuous improvement in GMP, pharmacopeia alignment, and pharmacovigilance systems.
- Innovation pipeline - scale clinical validation and modernization of classic TCM formulas to support evidence-based adoption.
- Sustainable supply chains - secure medicinal material traceability and ecological sourcing to protect long-term ingredient availability.
Strategic KPIs to measure progress toward the vision:
- Annual revenue CAGR target: 8-12% (near-term)
- Overseas revenue share target: 20% within 3-5 years
- R&D investment target: increase to 4-5% of revenue within 3 years
- New international registrations: 15-25 additional country approvals per triennium
- Maintain net profit margin: ~15%+ with improved operational efficiencies
For detailed investor context and who's buying into Pientzehuang's strategy, see: Exploring Zhangzhou Pientzehuang Pharmaceutical., Ltd Investor Profile: Who's Buying and Why?
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Vision Statement
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) positions its vision around becoming a first-class enterprise in the global pharmaceutical and healthcare markets by combining traditional Chinese medicine heritage with modern pharmaceutical practices. This vision is operationalized through a focus on sustainable innovation, ethical governance, collaborative culture, inclusiveness, and societal responsibility.- Innovation: continuous investment in R&D, product modernization, and digital transformation to adapt to shifting market needs and regulatory environments.
- Integrity: strict compliance, quality assurance, and transparent stakeholder communication to build long-term trust.
- Cooperation: strategic partnerships across clinical research, supply chain, and distribution to expand global reach.
- Inclusiveness: embracing diverse talent and perspectives to drive creativity and market relevance.
- Responsibility: environmental, social, and governance (ESG) practices that ensure accountability and positive social impact.
| Metric / Year | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Revenue (CNY, millions) | 3,200 | 3,750 | 4,200 |
| Net Profit (CNY, millions) | 610 | 720 | 820 |
| R&D Spend (CNY, millions) | 150 | 185 | 210 |
| R&D Spend (% of Revenue) | 4.7% | 4.9% | 5.0% |
| Gross Margin | 58.0% | 59.5% | 60.2% |
| Approx. Market Capitalization (CNY, billions) | - | 25 | 28 |
- R&D acceleration: scale clinical studies and formulation modernization-target R&D intensity maintained at ~5% of revenue to drive pipeline growth.
- Quality and compliance: certification upgrades and supply-chain traceability investments to support exports and international registrations.
- Digital & manufacturing transformation: smart factories and ERP upgrades to improve gross margins and reduce lead times.
- Global expansion: selective partnerships and registration efforts in Southeast Asia, Europe, and other markets to diversify revenue.
- ESG commitments: emissions, waste reduction programs, and community health initiatives to reinforce corporate responsibility.
| Target | Timeframe | Quantified Goal |
|---|---|---|
| Revenue growth | 3 years | Compound annual growth rate (CAGR) 8-10% |
| R&D intensity | 3 years | Maintain ≥5% of revenue |
| International revenue share | 5 years | Increase to 15-20% of total revenue |
| Net profit margin | 3 years | Improve to ≥20% |
| ESG targets | 3-5 years | Reduce scope 1/2 emissions intensity by 20%; implement community health programs in core regions |
- Management: allocate capital toward high-potential R&D projects and digital manufacturing upgrades.
- Investors: monitor KPIs tied to revenue growth, R&D yield, and margin improvements.
- Employees: continuous training programs to support inclusiveness and cooperation across functions and geographies.
- Partners: co-development and licensing agreements to accelerate global registrations and market entry.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.